A metastatic human melanoma cell line that produces urokinase-type plasminogen activator was stably transfected with cDNA encoding human plasminogen activator inhibitor 2 (PAI-2). Transfected clones expressed PAI-2 at levels two to nine times higher than both the parental cell line and mock transfectants, as detected by ELISA ofcell lysates and conditioned medium.
Invasion of surrounding tissues and metastasis to distant organs are the main clinical characteristics of malignant tumors. The pathobiological mechanisms enabling tumor cells to invade through occluding extracellular matrix (ECM) and to disseminate to distant organs remain to be elucidated. Various proteolytic enzymes elaborated by tumor cells have been implicated as important in invasion and metastasis (1, 2) .
Plasminogen activator (PA) and plasmin play a central role in tissue degradation and remodeling (3) . Plasmin, the active form of plasminogen, degrades ECM components such as fibronectin, laminin, and fibrin and also mediates activation of certain metalloproteinases. Two distinct activators of plasminogen are known, urokinase-type PA (uPA) and tissue-type PA, which are tightly controlled by specific PA inhibitors (PAls) namely, PAI-1 and PAI-2. The fine-tuned balance between PA and PAI activities is responsible for controlled pericellular proteolysis and appears to be lacking in tumor cells, resulting in continuous, uncontrolled proteolytic breakdown of the ECM by these cells, leading to tissue invasion and ultimately metastasis. Restoration of this balance by inhibition of tumor cell-derived PA activity should therefore result in suppression of invasion and metastasis.
Thus, inhibition of uPA by specific inhibitors or anticatalytic antibodies resulted in inhibition of tumor cell invasion and metastasis. PAI-1 and PAI-2 were shown to inhibit ECM degradation by human tumor cell lines in vitro (4) (5) (6) . Anti-uPA antibodies inhibited invasion and metastasis of a human squamous carcinoma cell line in chicken embryos (7) , local
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invasion of human tumors grown s.c. in mice (8) , and experimental metastasis of murine melanoma cells in mice (9) . Overexpression of uPA in poorly metastatic murine melanoma cells (10) or in H-ras-transformed NIH 3T3 fibroblasts (11) enabled these cells to form experimental metastases. Overexpression of enzymatically inactive uPA reduced metastasis of prostate carcinoma cells (12) .
We previously described the highly metastatic human melanoma cell line M24met (13) that secretes a spectrum of proteolytic enzymes, including type IV collagenases, interstitial collagenase, and uPA (14) . In vitro, this cell line degrades interstial and basement membrane matrices with uPAdependent removal of matrix glycoprotein as a prerequisite step preceding metalloproteinase-dependent collagenolysis. Consequently in this model the addition of exogenous recombinant PAI-2 inhibits dissolution of all matrix components (14) . Here, we address the role of PA activity in human melanoma metastasis in severe combined immunodeficient (SCID) mice. We stably transfected our metastatic melanoma cell line with full-length PAI-2 cDNA and analyzed the resulting transfectants for their ability to degrade ECM and to metastasize in SCID mice from s.c. tumors to distant organs, such as lymph nodes and lungs.
MATERIALS AND METHODS
Cell Culture. The human melanoma cell line M24met has been described (13) . For this study M24met cells were subcloned by limiting dilution, and a clonal line designated M24met/cl was established. M24met/cl cells were grown in RPMI 1640 medium 10% fetal bovine serum/2 mM glutamine.
Transfection. The full-length cDNA encoding for human PAI-2 was from E. K. 0. Kruithof (Lausanne, Switzerland). It was cloned into the unique EcoRI restriction site of the expression vector pEMSVSCRIBE-a2 (6) by using specific adaptors. M24met/cl cells were cotransfected with the simian virus 40-driven PAI-2 expression vector and pSV2-neo with the lipofectin reagent (GIBCO/BRL). Stable transfectants were isolated by neomycin selection (500 ,tg/ml). Mock transfectants were obtained under identical conditions using pSV2-neo and pEMSVSCRIBE-a2 without insert. PAI-2-expressing clones were identified in a fibrin agarose screening assay, as described (6) . PAI-2 antigen in conditioned medium (CM) and cell lysates was quantified by using the Imubind PAI-2 ELISA kit (ADI, Greenwich, CT agarose zymography (15) . SDS/PAGE gels were washed in 2.5% Triton X-100 and underlaid with a gel consisting of bovine fibrinogen (10 mg/ml), 2.5% low-temperature-geling agarose, thrombin, and plasminogen and, for reverse zymography only, also uPA. Zones of lysis were evaluated after 8-to 12-hr incubation at 37°C. Immunoblotting. Serum-free CM, neutralized eluates, or cell lysates were generated, as described (16) , separated on SDS/10% PAGE, and electroblotted onto nitrocellulose membranes. Primary antibodies were goat anti-human uPA, rabbit anti-human uPA receptor (uPAR) (ADI), and rabbit anti-human PAI-2 antiserum (E. K. 0. Kruithof).
Matrix Degradation. Degradation of radiolabeled ECM produced by R22C1D rat smooth muscle cells in vitro was determined as described (14) . Cells (2 x 105/35-mm dish) in complete tissue culture medium were seeded onto the matrices. Radioactivity released into the supernatant was determined at the times indicated, and cumulative counts were plotted after subtraction of counts released by medium alone. After 13 days tumor cells were lysed with 0.025 M (NH4)OH, and the residual matrices were analyzed by sequential enzyme treatment (14) .
Spontaneous Metastasis Assay. Tumor cells (2 x 106 in 100
,ll of phosphate-buffered saline) were injected s.c. into the flank of female, 6-to 8-week-old CB1.7 scid/scid mice. Tumors were measured with calipers, and volumes were calculated as (a2xb)/2, where a is the width and b is the tumor length. When the tumors reached a volume of -1000 mm3, usually on day 15 after injection, they were fixed in 10% buffered formalin and stained with Gomori's trichrome stain to visualize collagen fibers and tumor capsules. Twenty-one days after removal of the primary tumor, mice were sacrificed, and the extent of metastasis was evaluated. To this end, lungs were fixed in Bouins' fixative and examined under a low-magnification microscope for tumor foci on their surfaces. Enlarged lymph nodes were excised and weighed.
RESULTS
The human melanoma cell line M24met/cl was stably transfected with cDNA encoding for human PAI-2. Neomycinresistant colonies arising from single cells were grown to subconfluency in 35-mm dishes and screened for PAI activity in aliquots of serum-free medium with a reverse fibrin-agarose plate assay. Six clones, PAI-2-2, PAI-2-4, PAI-2-6, PAI-2-13, PAI-2-25, and PAI-2-35, expressing different levels of PAI-2, were selected for this study. Two mock-transfected clones and the parental cell line were selected as controls.
The amount of PAI-2 produced, as measured by ELISA, remained unchanged after mock transfection but increased for all PAI-2 transfectants (Table 1 ). In cell lysates of the PAI-2 transfectants, PAI-2 protein increased from 2.9-fold to 4.7-fold, whereas the amount of PAI-2 released into the CM increased from 2-fold (PAI-2-25) to 10.7-fold (PAI-2-4) as compared with the parental cell line. M24met/cl and the transfected cell lines also produced low levels of PAI-1, typically 60 ng per 106 cells, that did not change upon transfection with cDNA for PAI-2. Eluates and CM from clones grown under serum-free conditions were examined for PA and PAI activities by regular and reverse fibrin overlay zymography, respectively. uPA activity was detectable on the surface and in CM of control lines, as well as in the PAI-2 transfectants expressing low levels of PAI-2 (Fig. 1) ; however, uPA activity was diminished in clone PAI-2-35 and absent from clone PAI-2-4. Accordingly, PAI activity in the CM was found for all PAI-2 transfectants but was lacking in the controls. Cellsurface-bound PAI activity was detectable only for the highest PAI-2-expressing clones PAI-2-4 and PAI-2-35.
Both uPA and PAI-2 were demonstrated in the supernatants and after acidic elution from the cell surface by immunoblotting. Soluble uPA was demonstrated for all cell lines tested ( Fig. 2A) . A nonspecific increase in uPA expression upon stable transfection has been observed earlier (6) . It was notable that all transfected cell lines produced more uPA than the parental cell line. Because the cells were grown in serum-free medium-i.e., in the absence of plasmin, most uPA is present in the enzymatically inactive proform, thus escaping detection by fibrin overlay. PAI-2 was detectable by immunoblotting only in the supernatant of cells transfected to overexpress PAI-2. Distinct bands of surfacebound uPA (52 kDa) were detected in such eluates from all cell lines (Fig. 2B ). In addition, the anti-uPA antibody stained uPA-PAI complexes (102 kDa) from the surface of the PAI-2-transfected cell lines. Anti-PAI-2 antibodies detected a glycosylated and a nonglycosylated form of PAI-2 (59 and 47 kDa, respectively), as well as PA-PAI-2 complexes on the surface of PAI-2-transfected cells (Fig. 2B ), but not on the surface of the control cells. It is most likely that uPA, PAI-2, and uPA-PAI are bound to the cell surfaces through specific interaction with the receptor for uPA. Immunoblots with anti-uPAR antibodies showed that lysates from all cells produced similar bands for uPAR which is apparently present in a glycosylated and a nonglycosylated form (Fig. 2C) . Additional bands may represent uPAR complexed with intact or partially degraded uPA. Together, these data indicate that transfection with PAI-2 cDNA increased PAI-2 expression by M24met cells and reduced PA activity on the cell surface. The ability of M24met/cl melanoma cells to degrade radiolabeled ECM in vitro correlated inversely with their production of PAI-2. M24met/cl cells and mock transfectants degraded smooth muscle cell matrices most efficiently (Fig. 3) . Transfectants PAI-2-2, PAI-2-6, PAI-2-13, and PAI-2-25 were -50% inhibited compared with controls. PAI-2-35 and PAI- Analysis of the matrix components remaining after 13 days of digestion revealed that control cells had solubilized '60% of the trypsin-sensitive material, whereas PAI-2 transfectants had solubilized between 36% (PAI-2-25) and 11% (PAI-2-4) of the trypsin-sensitive material. Expression of PAI-2 resulted also in a slight decrease in degradation of matrix elastin but had no significant effect on collagen solubilization.
Transfected and control cells formed rapidly growing tumors when injected s.c. into the flank of SCID mice. Tumors of similar size were removed 15 days after injection (Table 2 ). Histological analysis demonstrated that PAI-2-4 and PAI-2-35 tumors produced capsules of dense connective tissue (Fig. 4) . In contrast, such capsules were absent from tumors derived from control cells and transfectants expressing low levels of PAI-2.
The extent of spontaneous metastasis of M24met/cl cells and transfectants in SCID mice correlated inversely with the amount of PAI-2 produced. From s.c. tumors M24met/cl cells and mock transfectants metastasized in all mice to draining lymph nodes and lungs where they formed extensive secondary tumors (Table 2 ). Pulmonary metastases in these control mice were so numerous that they replaced practically the total surface of the lungs with tumor tissue. Few differences in spontaneous metastasis were observed between the control cell lines and clones PAI-2-25 and PAI-2-6, which produce moderate levels of PAI-2. Clone PAI-2-25, however, generated fewer lung metastases than the control cell lines, resulting in high but countable numbers of pulmonary foci. In contrast, spontaneous metastasis of the high-producing clones PAI-2-35 and PAI-2-4 was greatly inhibited. Thus, clone PAI-2-35 generated significantly fewer pulmonary metastases and much smaller tumor deposits in the draining lymph nodes than parental or mock-transfected cells. Clone PAI-2-4, producing the highest amounts of PAI-2, showed no evidence of melanoma metastasis to the draining lymph nodes in 77% of the inoculated animals and no metastasis to the lungs in 31% of the animals. In the remaining mice, inoculation of PAI-2-4 generated small numbers of tumor foci in the lungs and produced a moderate increase in the weight of involved lymph nodes. Taken together, these data indicate that PAI-2-mediated neutralization of uPA activity suppresses human melanoma invasion and metastasis in SCID mice.
DISCUSSION
Malignant cells have to pass through ECM several times, to complete the metastatic process (17) . ECM presents a dense network of collagen fibers, glycoproteins, proteoglycans, and other proteins, and it is generally believed that tumor cells need to proteolytically degrade this barrier in order to cross it (1, 2) . Among the proteolytic enzymes produced by different tumor cells, uPA is one of the most prominent. Here, we demonstrate that reducing net uPA activity in a metastatic human melanoma cell line inhibits its metastatic behavior. To this end, we stably transfected our M24met/cl cell line with cDNA encoding for the PA inhibitor PAI-2. Accordingly, PAI-2 overexpression resulted in reduced PA activity on the surface of melanoma cells and in the inhibition of these cells' abilities to degrade ECM in vitro. In vivo, PAI-2 overexpression resulted in the formation of a fibrous The cellular receptor for uPA, uPAR, is thought to play a critical role in the regulation of tumor-associated PA activity (18, 19) . Thus, on the surface of tumor cells uPAR can focus proteolytic activity to discrete areas on the cell membrane and possibly to the invasive edge of a tumor. Our data suggest a role for uPAR in melanoma invasion and metastasis, in that PAI-2 overexpression reduced uPA activity in cell CM and also on the cell surface. Cell-surface-bound PA activity was abolished in the cell line PAI-2-4, which expressed the highest amounts of PAI-2 and was the least metastatic. Immunoblotting demonstrated that uPA on the surface of PAI-2-4 cells largely occurred as a complex with PAI; however, overall uPA on the surface of PAI-2-4 appeared reduced compared with other cell lines. This might be the result of an enhanced rate of uPA internalization consistent with the finding of others that uPA-PAI complexes, but not uPA alone, are internalized rapidly through uPAR (20) .
We demonstrate here that the ability of M24met/cl melanoma cells to dissolve ECM correlated inversely with their overexpression of PAI-2. This agrees with earlier findings that exogenous, recombinant PAI-2 (5, 14) or overexpression of PAI-2 by tumor cells (6) can prevent malignant cells from degrading matrix glycoproteins in vitro. In the skin of SCID mice, transfected cells that produced five to nine times more PAI-2 than the parental cell line formed tumors surrounded by a dense, fibrous capsule. Formation of a peritumoral capsule was also observed when different tumor cell lines were transfected to overexpress protease inhibitors (6, 21) . Whether such capsules are produced by the tumor cells or by the normal tissue surrounding the tumor remains to be determined. Metastatic melanoma cells produce uPA, but also tissue factor, the cellular activator of the coagulation cascade (22) . Tissue factor has been implicated in the formation of experimental, hematogenous metastasis (22) ; however, its activity may be counterproductive for melanoma cell intravasation from the primary tumor, causing the formation of a tumor capsule that can only be overcome by PA activity.
In our studies, we used a highly metastatic human melanoma cell line that produces both lymphatic and hematogenous metastasis. Overexpression of PAI-2 in these cells correlated with inhibition of metastasis to lymph nodes and to lungs, resulting in no apparent metastasis in several mice inoculated with PAI-2-4 cells. However, complete inhibition of spontaneous metastasis was not observed for all animals inoculated with PAI-2-4, indicating that the PAI-2 expression levels achieved were suboptimal or the lack of inhibition of other proteinases.
Here, we demonstrate for human melanoma that overexpression of PAI-2 inhibits metastasis, implying a functional role for PA in this process. Earlier, a study of six different melanoma cell lines (23) indicated a positive correlation between uPA production and the ability of the cells to spontaneously metastasize in nude mice. Furthermore, in the tumor progression of human melanoma, plasminogen activation appears to be a late event associated with advanced primary tumors and metastases (24) based on the finding that expression of uPA and uPAR, but also of PAI-1 and PAI-2, are not detectable in benign and early stages but appear frequently in later stages of melanoma progression. PA activity has also been implied for the biology of other solid tumors, including prostate carcinoma (12) and colon carcinoma (18) . High levels of uPA in breast cancer tissues correlate significantly with shortened overall patient survival (25) , and recently, a tumorsuppressor gene has been identified in breast carcinoma (26) that encodes for maspin, a serine protease inhibitor with significant sequence similarity to PAI-2.
In conclusion, we transfected a highly metastatic human melanoma cell line with PAI-2 cDNA and found the cell lines overexpressing PAI-2 to be inhibited in their ability to degrade ECM and to metastasize spontaneously from primary tumors to distant organs. Thus, our present data provide direct evidence for a requirement of (cell bound) uPA activity for human melanoma invasion and metastasis.
